

Magnetic Resonance Imaging of the Hand in Systemic Sclerosis

ANDREA H.L. LOW, MATTHEW LAX, SINDHU R. JOHNSON, and PETER LEE

ABSTRACT. Objective. To evaluate the utility of magnetic resonance imaging (MRI) in systemic sclerosis (SSc)-associated arthropathy.

Methods. MRI of the hand was performed in patients presenting with joint pain/swelling in order (1) to determine the frequency of inflammation on MRI, and (2) to compare MRI with radiography.

Results. Of 17 patients with SSc, 10 (59%) had inflammatory MRI findings with synovitis (n = 8), erosions (n = 7), joint effusion (n = 7), or tenosynovitis (n = 8). Bone edema was present in 9 patients. Of 7 patients with MRI erosions, only 2 had radiographic erosions.

Conclusion. Our study illustrates the usefulness of MRI in the accurate diagnosis and characterization of SSc-associated arthropathy. (First Release April 1 2009; J Rheumatol 2009;36:961–4; doi:10.3899/jrheum.080795)

Key Indexing Terms:

SYSTEMIC SCLEROSIS MAGNETIC RESONANCE IMAGING HAND ARTHROPATHY

Joint involvement in systemic sclerosis (SSc) is disabling¹ and can be a result of arthritis, overlying skin tightness, flexion contractures, or fibromyalgia, which can be clinically challenging to determine accurately. Joint pain occurs in 24% to 97% of patients with SSc² and in late disease may be due to synovial fibrosis without underlying synovitis³.

Radiographic abnormalities in SSc are well described^{2,4,5}. The utility of magnetic resonance imaging (MRI) in evaluating SSc-associated arthropathy has not previously been described. MRI is able to reveal the extent of synovitis, tenosynovitis, and effusions contributing to the joint symptoms and to differentiate these from skin or soft tissue involvement, especially in early disease. This has significant therapeutic implications. With active synovitis, the early use of disease modifying antirheumatic drug or tumor necrosis factor- α inhibitors^{6,7} may prevent progressive joint damage and loss of function.

The aim of our study was (1) to determine the prevalence of inflammation on MRI, and (2) to compare MRI with radiography in patients with SSc presenting with joint pain/swelling of the hands.

From the Department of Medicine, Division of Rheumatology, and Department of Medical Imaging, Division of Musculoskeletal Imaging, University of Toronto, Mount Sinai Hospital, Toronto, Ontario, Canada.

Dr. Johnson is supported by The Abbott Scholar Award for Rheumatology Research and a Canadian Arthritis Network Fellowship.

A.H.L. Low, BMBS, MRCP (UK), FAMS (Rheumatology), Clinical Fellow, Division of Rheumatology, Department of Medicine,

University of Toronto, Mount Sinai Hospital; M. Lax, MD, FRCPC, Assistant Professor, Department of Medical Imaging, University of Toronto, Mount Sinai Hospital; S.R. Johnson, MD, FRCPC, Clinical Associate; P. Lee, MB, CHB, MD, FRCPC, FRACP, Professor of Medicine, Division of Rheumatology, Department of Medicine, University of Toronto, Mount Sinai Hospital.

Address reprint requests to Dr. A.H.L. Low, Mount Sinai Hospital, Room 2-004, Box 9, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada.

E-mail: hsiulinglow@gmail.com

Accepted for publication December 24, 2008.

MATERIALS AND METHODS

Patients. Patients > 18 years of age with SSc fulfilling American College of Rheumatology (ACR) classification criteria⁸ were included if they (1) had a history of joint pain/swelling of the hand/wrist and (2) agreed to have an MRI of the hand/wrist. The study was approved by the institutional research ethics board.

Medical records were reviewed for (1) demographic data (sex, age, disease duration from the time of SSc diagnosis, subtype according to LeRoy, *et al*⁹, onset of first joint symptoms); (2) rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) status; and (3) examination findings on visit prior to MRI [tender and swollen joint counts (TJC/SJC), tenosynovitis, and flexion contractures in the hands and wrists only].

Radiology. Standard anterior-posterior radiographs of the hands and wrists were obtained. MRI of the hand/wrist was performed on a 1.0 or 1.5 Tesla MRI device with dedicated surface coils. Nonenhanced axial and coronal T1-weighted spin-echo imaging, plus either short-tau inversion recovery (STIR) or fast spin-echo T2-weighted fat suppressed sequences were performed in all patients. MRI and radiographs were reviewed by an independent radiologist blinded to the patients' clinical detail. Results were recorded according to 4 predefined categories as appropriate for the mode of imaging as (1) articular [presence of joint space narrowing (JSN), erosion, synovitis, and effusion]; (2) soft tissue (calcification, tenosynovitis); (3) bone (osteopenia, bone resorption, bone edema); or (4) degenerative (subchondral sclerosis, bone cyst, osteophyte, or JSN plus one of the above).


Radiographic erosion was defined as interruption of the cortical surface. Inflammation on MRI was defined as any one of synovitis (synovial thickening on T1-weighted images and high signal intensity on STIR/T2-weighted images); erosion (a sharply marginated bone lesion visible in 2 planes with a cortical break in at least 1 plane); joint effusion (low signal intensity on T1-weighted images and high signal intensity on STIR/T2-weighted images with correct localization); or tenosynovitis (high signal intensity on STIR/T2-weighted images with correct localization). Bone edema was defined as a lesion in trabecular bone with ill-defined margins of high signal intensity on T2-weighted images.

RESULTS

Seventeen patients (10 diffuse, 7 limited SSc) were recruited; 14 had a history of symmetrical joint symptoms.

Inflammatory findings on MRI. Ten (59%) patients had inflammatory findings on MRI. Eight (47%) had synovitis,

A



B




Figure 1. A. Enhanced MRI image of metacarpophalangeal (MCP) joints (Patient 4). Arrowhead: bone edema; long arrow: flexor tenosynovitis; short arrow: synovitis. B. MRI/STIR image of MCP joints (Patient 2; hand radiographs showed no erosions). Arrowhead: bone edema; long arrow: bone erosion.

Table 2. Characteristics of patients with (Group 1) and without (Group 2) inflammation on MRI scan.

	Sex/Disease Subtype	Age at Diagnosis, yrs	Disease Duration at 1st Joint Symptoms, yrs	Disease Duration at MRI, yrs	Time to MRI*, days	Clinical Examination			RF/ Anti-CCP
						TJC/SJC	Tenosynovitis	FFC	
Group 1									
2	F/L	22	12.0	12.3	14	2/6	–	–	–/–
4	M/L	68	0.0	1.9	31	20/10	–	–	–/UK
5	F/D	32	–2.0	0	13	18/0	–	+	22/–
6	F/D	36	UK	16.3	12	16/1	–	–	24/–
7	M/L	60	–0.8	1.5	70	0/ND	–	+	40/–
8	F/L	46	UK	13.7	8	0/0	+	–	–
11	M/D	44	–1.2	0	21	0/10	–	–	–
13	F/L	59	1.9	2.3	44	1/1	+	–	–
16	F/L	50	–1.6	2.3	49	4/0	–	–	48/18
17	M/D	37	UK	13.5	48	1/0	–	+	–
Median (range)		45 (22–68)	–0.8 (–2.8–12.0)	2.3 (0–16.3)	26 (8–70)	2/1			
Group 2									
1	F/L	52	–1	0	13	22/7	–	–	32/–
3	M/D	39	UK	0.5	41	2/0	–	–	–/–
9	M/D	45	–0.2	2.6	53	8/3	–	–	25/UK
10	F/D	54	UK	3.0	34	3/4	–	–	–/–
12	MD	37	UK	0.7	33	10/0	–	+	–/UK
14	F/D	48	–0.5	7.3	55	7/4	–	–	–/–
15	M/D	46	–0.4	0.2	33	19/4	–	+	249/90
Median (range)		46 (37–54)	–0.5 (–1.0 to –0.2)	0.7 (0–7.3)	34 (13–55)	8/4			

* Time to MRI (from date of clinical examination). +: present, –: absent; L: limited, D: diffuse. TJC: tender joint count, SJC: swollen joint count, FFC: finger flexion contracture, ND: not determined (whole hand swollen), UK: unknown, RF: rheumatoid factor (negative < 20 IU/ml), anti-CCP: anti-citrullinated peptide antibody (negative ≤ 5 U/ml).

must be interpreted with caution. Although contrast-enhanced T1-weighted images would have been the optimal method in delineating synovitis according to RA OMERACT (Outcome Measures in Rheumatology) guidelines¹², this was not routinely done due to concerns regarding nephrogenic systemic fibrosis¹³.

Our study illustrates the usefulness of MRI in the accurate diagnosis of SSc-associated arthropathy. This pilot study provides a basis for prospective studies to investigate the implications of MRI joint abnormalities in SSc in terms of early aggressive treatment and improved outcomes.

REFERENCES

- Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. *J Rheumatol* 2006;33:1117-22.
- Baron M, Lee P, Keystone EC. The articular manifestations of progressive systemic sclerosis (scleroderma). *Ann Rheum Dis* 1982;41:147-52.
- Rodnan GP. The nature of joint involvement in progressive systemic sclerosis (diffuse scleroderma). *Ann Intern Med* 1962;56:422-39.
- Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. *Ann Rheum Dis* 2006;65:1088-92.
- Blocka KL, Bassett LW, Furst DE, Clements PJ, Paulus HE. The arthropathy of advanced progressive systemic sclerosis. A radiographic survey. *Arthritis Rheum* 1981;24:874-84.
- Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. *J Rheumatol* 2007;34:1636-7.
- Alkassab F. Overlap of systemic sclerosis and rheumatoid arthritis. *J Rheumatol* 2007;34:1593-4.
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980;23:581-90.
- LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. *J Rheumatol* 1988;15:202-5.
- Allanore Y, Seror R, Chevrot A, Kahan A, Drape JL. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. *Arthritis Rheum* 2007;56:2747-54.
- Ingegnoli F, Galbiati V, Zeni S, et al. Use of antibodies recognizing cyclic citrullinated peptide in the differential diagnosis of joint involvement in systemic sclerosis. *Clin Rheumatol* 2007;26:510-4.
- Ostergaard M, Peterfy C, Conaghan P, et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system. *J Rheumatol* 2003;30:1385-6.
- Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. *Eur J Radiol* 2008;66:230-4.